文献速递消化系统肿瘤

年龄与合并症对日本老年结直肠癌患者预后及辅助化疗应用的影响:一项回顾性多中心研究

Influence of age and comorbidity on prognosis and application of adjuvant chemotherapy in elderly Japanese patients with colorectal cancer: A retrospective multicentre study.
PubMed 文献 · Eur J Cancer · 2017-06-13

该回顾性多中心研究分析了4598例2004至2006年接受根治性手术的结直肠癌患者,发现年龄和合并症影响总生存,且75岁及以上III期患者接受辅助治疗的比例(结肠癌35%、直肠癌21%)远低于年轻患者,高龄患者无论合并症评分如何均存在治疗不足。

要点

  • 年龄<64岁、65-74岁和≥75岁患者分别为2007例(44%)、1614例(35%)和977例(21%)。
  • ≥75岁III期结直肠癌患者中,结肠癌35%、直肠癌21%接受辅助治疗,远低于年轻患者。
  • ≤74岁患者辅助治疗的应用取决于合并症评分,而高龄患者则不然。

核心结论

  • 年龄和合并症恶化了接受根治性手术的结直肠癌患者的总生存。
  • ≥75岁患者尽管辅助治疗可能改善总生存,但无论合并症评分如何均存在治疗不足。

研究设计与样本

  • 日本结直肠癌术后随访研究组利用汇总数据进行的回顾性多中心研究,共纳入4598例(结肠癌3304例,直肠癌1294例)2004至2006年接受根治性手术的患者,分析年龄、Charlson合并症评分、肿瘤标志物阳性、辅助治疗与预后。

主要发现

  • 年龄<64岁、65-74岁和≥75岁患者分别为2007例(44%)、1614例(35%)和977例(21%)。
  • 各年龄组间肿瘤部位、肿瘤标志物阳性、临床分期、辅助治疗实施、Charlson合并症评分和总生存均存在显著差异(P < 0.0001)。
  • ≥75岁III期结直肠癌患者中,结肠癌35%、直肠癌21%接受辅助治疗,这些比例远低于年轻患者。
  • ≤74岁患者辅助治疗的应用取决于Charlson合并症评分,而高龄患者则不然。
  • 在老年III期结直肠癌患者中,性别、癌胚抗原浓度和辅助治疗与总生存显著相关。

关键数值与推荐

  • 各年龄组间肿瘤部位、肿瘤标志物阳性、临床分期、辅助治疗实施、Charlson合并症评分和总生存差异的P < 0.0001。
  • ≥75岁III期结肠癌患者接受辅助治疗的比例为35%,直肠癌为21%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adjuvant therapy for colorectal cancer (CRC) in patients aged ≥75 years is supported by inadequate evidence, although such patients are increasing in number worldwide. PATIENTS AND METHODS: We assessed the influence of age and comorbidities on the prognosis of CRC in elderly patients using pooled data by the Japanese Study Group for Postoperative Follow-up of Colorectal Cancer. In total, 4598 patients (3304 with colon cancer and 1294 with rectal cancer) who underwent curative surgery from 2004 to 2006 were analysed with respect to age, Charlson comorbidity score (CS), tumour marker positivity, adjuvant therapy and prognosis. RESULTS: The number of patients aged <64, 65-74 and >75 years was 2007 (44%), 1614 (35%) and 977 (21%), respectively. Tumour location, tumour marker positivity, clinical stage, performance of adjuvant therapy, CS and overall survival (OS) were significantly different among these age groups (P < 0.0001). Among patients aged ≥75 years with stage III CRC, 35% with colon cancer and 21% with rectal cancer received adjuvant therapy; these proportions were much lower than those in younger patients. Application of adjuvant therapy was dependent on the CS in patients aged ≤74 years, but not in older patients. Sex, the carcinoembryonic antigen concentration and adjuvant therapy were significantly associated with OS in elderly patients with stage III CRC. CONCLUSION: Age and comorbidities worsened the OS of patients with CRC who underwent curative surgery. However, patients aged ≥75 years were undertreated regardless of their CS despite the possibility of OS improvement by adjuvant therapy.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Yamano T, Yamauchi S, Kimura K, et al. Influence of age and comorbidity on prognosis and application of adjuvant chemotherapy in elderly Japanese patients with colorectal cancer: A retrospective multicentre study. Eur J Cancer. 2017. PMID: 28622612. doi:10.1016/j.ejca.2017.05.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。